Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Parexel International Corp.

http://www.parexel.com

Latest From Parexel International Corp.

Digital Scrip Awards Celebrate Biopharma After An Exceptional Year

The big winners of the night were AstraZeneca and Roche as pharma, biotech and allied industries came together online on 2 December to celebrate during a ceremony hosted by Ed Balls.

Companies Research & Development

Digital Acceleration: Low-Hanging Fruit And Stretch Goals

COVID-19 has pushed the entire health care system to adopt new technologies and new solutions for conducting clinical research and delivering care to patients. An expert panel hosted by the Galien Foundation provided a meditation on what the biopharma industry has learned so far, and how to use the urgency created by COVID-19 to lock-in technological acceleration while maintaining what FDA’s Amy Abernethy called  “responsible progress.”

Coronavirus COVID-19 Digital Health

Postmarket Safety Signal Evaluation: US FDA ‘MAPPS’ Out New Approach

For drug sponsors, FDA's revised process could mean more public disclosures about potential safety risks and more regulatory actions to address those risks. CDER seeks to better leverage scientific and regulatory expertise, including in product quality and compliance, in investigating safety signals under the new policy manual, which also includes target timelines for action.

Drug Safety Post Market Regulation & Studies

Who's Hired? Teva And Lupin Shake Up Supply Chain

Teva has announced a leadership change in its global operations, while Lupin has made a key appointment to focus on quality and compliance. Among other changes in leadership roles, Olainfarm has seen one of its six management board members resign. 

Appointments Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
UsernamePublicRestriction

Register